Review




Structured Review

Broad Institute Inc breast cancer microarray dataset
Breast Cancer Microarray Dataset, supplied by Broad Institute Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/breast cancer microarray dataset/product/Broad Institute Inc
Average 90 stars, based on 1 article reviews
breast cancer microarray dataset - by Bioz Stars, 2026-06
90/100 stars

Images



Similar Products

86
Thermo Fisher public breast cancer affymetrix hgu133a microarray datasets
Total number of patients, number of patients in each class, and sources of the datasets used in single- and multiomics prediction experiments. <xref ref-type= a " width="250" height="auto" />
Public Breast Cancer Affymetrix Hgu133a Microarray Datasets, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/public breast cancer affymetrix hgu133a microarray datasets/product/Thermo Fisher
Average 86 stars, based on 1 article reviews
public breast cancer affymetrix hgu133a microarray datasets - by Bioz Stars, 2026-06
86/100 stars
  Buy from Supplier

90
Thermo Fisher microarray breast cancer datasets
Total number of patients, number of patients in each class, and sources of the datasets used in single- and multiomics prediction experiments. <xref ref-type= a " width="250" height="auto" />
Microarray Breast Cancer Datasets, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/microarray breast cancer datasets/product/Thermo Fisher
Average 90 stars, based on 1 article reviews
microarray breast cancer datasets - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier

90
Biotechnology Information breast cancer microarray datasets
Total number of patients, number of patients in each class, and sources of the datasets used in single- and multiomics prediction experiments. <xref ref-type= a " width="250" height="auto" />
Breast Cancer Microarray Datasets, supplied by Biotechnology Information, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/breast cancer microarray datasets/product/Biotechnology Information
Average 90 stars, based on 1 article reviews
breast cancer microarray datasets - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier

90
Rosetta Inpharmatics breast cancer microarray datasets
Total number of patients, number of patients in each class, and sources of the datasets used in single- and multiomics prediction experiments. <xref ref-type= a " width="250" height="auto" />
Breast Cancer Microarray Datasets, supplied by Rosetta Inpharmatics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/breast cancer microarray datasets/product/Rosetta Inpharmatics
Average 90 stars, based on 1 article reviews
breast cancer microarray datasets - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier

90
Agilent technologies microarray breast cancer dataset
Total number of patients, number of patients in each class, and sources of the datasets used in single- and multiomics prediction experiments. <xref ref-type= a " width="250" height="auto" />
Microarray Breast Cancer Dataset, supplied by Agilent technologies, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/microarray breast cancer dataset/product/Agilent technologies
Average 90 stars, based on 1 article reviews
microarray breast cancer dataset - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier

90
Broad Institute Inc breast cancer microarray dataset
Total number of patients, number of patients in each class, and sources of the datasets used in single- and multiomics prediction experiments. <xref ref-type= a " width="250" height="auto" />
Breast Cancer Microarray Dataset, supplied by Broad Institute Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/breast cancer microarray dataset/product/Broad Institute Inc
Average 90 stars, based on 1 article reviews
breast cancer microarray dataset - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier

86
Thermo Fisher breast cancer affymetrix hg u133a microarray dataset
Total number of patients, number of patients in each class, and sources of the datasets used in single- and multiomics prediction experiments. <xref ref-type= a " width="250" height="auto" />
Breast Cancer Affymetrix Hg U133a Microarray Dataset, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/breast cancer affymetrix hg u133a microarray dataset/product/Thermo Fisher
Average 86 stars, based on 1 article reviews
breast cancer affymetrix hg u133a microarray dataset - by Bioz Stars, 2026-06
86/100 stars
  Buy from Supplier

Image Search Results


Total number of patients, number of patients in each class, and sources of the datasets used in single- and multiomics prediction experiments. <xref ref-type= a " width="100%" height="100%">

Journal: Bioinformatics

Article Title: COmic: convolutional kernel networks for interpretable end-to-end learning on (multi-)omics data

doi: 10.1093/bioinformatics/btad204

Figure Lengend Snippet: Total number of patients, number of patients in each class, and sources of the datasets used in single- and multiomics prediction experiments. a

Article Snippet: We trained COmic models on six different public breast cancer Affymetrix HGU133A microarray datasets (GSE11121, GSE1456, GSE2034, GSE2990, GSE4922, and GSE7390) that were previously used to benchmark knowledge-based classification methods that use interaction network priors.

Techniques:

(A ) Cross-validation performance of COmic models compared to previously published methods. The boxplots show the 10 mean auROC validation scores of a 10-times repeated 10-fold cross-validation over each of the 6 breast cancer cohorts. Performance of COmic models is shown in orange (last two boxes on the right side). The center line of each box indicates the median. The height of the boxes represents the interquartile range (IQR) with the upper and lower whiskers set to 1.5 times the IQR. Outliers are depicted by black diamonds. Notches represent the confidence interval (CI) around the median and were calculated using bootstrapping with 10 000 iterations. (B) Visualizing the global interpretation capabilities of a pooling-based COmic model. Each box represents one of the 50 pathways and was created using the pathway weights of the models trained on the six publicly available breast cancer cohorts: GSE11121, GSE1456, GSE2034, GSE2990, GSE4922, and GSE7390. The boxplots are defined as in (A) but without notches (CIs not shown). (C) Visualizing the local interpretation capabilities of an attention-based COmic model. Each heat-map shows the attention weights for each of the 50 pathways for three different patients. The model was trained on the GSE11121 cohort. Patient 1 was correctly classified to have a metastasis-free survival (DMFS) above 5 years. Patient 2 was correctly classified to have a DMFS below 5 years. Patient 3 was wrongly classified to have a DMFS above 5 years, while the DMFS of Patient 3 was actually below 5 years. More examples can be found in the supplement. (D) Mean training time of pooling-based and attention-based COmic models for differently sized datasets. The number of samples is 100, 1000, 10 000, and 100 000, respectively. Training was repeated five times per dataset and the stars represent the mean training time. The blue and green lines show the results for a fixed batch size of 32 samples per batch. The red and yellow lines show the results for an adaptive batch size of 1% of the dataset size (i.e. the batch size was 1 for the dataset with 100 samples and 1000 for the dataset with 100 000 samples). Each model was trained for 200 epochs.

Journal: Bioinformatics

Article Title: COmic: convolutional kernel networks for interpretable end-to-end learning on (multi-)omics data

doi: 10.1093/bioinformatics/btad204

Figure Lengend Snippet: (A ) Cross-validation performance of COmic models compared to previously published methods. The boxplots show the 10 mean auROC validation scores of a 10-times repeated 10-fold cross-validation over each of the 6 breast cancer cohorts. Performance of COmic models is shown in orange (last two boxes on the right side). The center line of each box indicates the median. The height of the boxes represents the interquartile range (IQR) with the upper and lower whiskers set to 1.5 times the IQR. Outliers are depicted by black diamonds. Notches represent the confidence interval (CI) around the median and were calculated using bootstrapping with 10 000 iterations. (B) Visualizing the global interpretation capabilities of a pooling-based COmic model. Each box represents one of the 50 pathways and was created using the pathway weights of the models trained on the six publicly available breast cancer cohorts: GSE11121, GSE1456, GSE2034, GSE2990, GSE4922, and GSE7390. The boxplots are defined as in (A) but without notches (CIs not shown). (C) Visualizing the local interpretation capabilities of an attention-based COmic model. Each heat-map shows the attention weights for each of the 50 pathways for three different patients. The model was trained on the GSE11121 cohort. Patient 1 was correctly classified to have a metastasis-free survival (DMFS) above 5 years. Patient 2 was correctly classified to have a DMFS below 5 years. Patient 3 was wrongly classified to have a DMFS above 5 years, while the DMFS of Patient 3 was actually below 5 years. More examples can be found in the supplement. (D) Mean training time of pooling-based and attention-based COmic models for differently sized datasets. The number of samples is 100, 1000, 10 000, and 100 000, respectively. Training was repeated five times per dataset and the stars represent the mean training time. The blue and green lines show the results for a fixed batch size of 32 samples per batch. The red and yellow lines show the results for an adaptive batch size of 1% of the dataset size (i.e. the batch size was 1 for the dataset with 100 samples and 1000 for the dataset with 100 000 samples). Each model was trained for 200 epochs.

Article Snippet: We trained COmic models on six different public breast cancer Affymetrix HGU133A microarray datasets (GSE11121, GSE1456, GSE2034, GSE2990, GSE4922, and GSE7390) that were previously used to benchmark knowledge-based classification methods that use interaction network priors.

Techniques: